A Postdoctoral Research Fellow position is available for a qualified scientist to join the laboratory of Stanley Riddell in the Program in Immunology at the Fred Hutchinson Cancer Research Center to develop specific T cell therapy for multiple myeloma. A major focus of the Riddell laboratory is the development of targeted adoptive immunotherapy for cancer by engineering distinct subsets of T cells with synthetic chimeric antigen receptors (CARs) or T cell receptors that selectively recognize malignant cells. The lab has developed methods to rapidly isolate defined populations of T cells that can be genetically modified to express tumor-targeting chimeric antigen receptors (CARs) and formulated in a defined composition. A CD19 antigen-targeting CAR-T therapy, developed by Dr. Riddell and Fred Hutch colleagues has advanced to the clinic and is achieving remissions in patients with refractory leukemia and lymphoma.
The lab is now pursuing targets for adoptive T-cell therapy of multiple myeloma and the current position will focus on using state-of-the-art methods to design and optimize CAR(s) in pre-clinical studies in the laboratory.
A Ph.D. and/or M.D. in immunology or a closely related field, and experience with a range of molecular biology techniques involving PCR, DNA sequencing, and construction of recombinant plasmid or viral vectors is essential. Experience in multiparameter flow cytometry and culture and characterization of CD8+ and CD4+ T cells, and tumor cells is also essential. Preference will be given to individuals with research interest in tumor immunology. Working with mouse models and familiarity with assays of immune cell function is advantage. Good written and verbal communication skills are highly appreciated.
If interested, please apply online at http://track.tmpservice.com/ApplyClick.aspx?id=2231358-2647-6621